ProShares Ultra Bloomberg Natural Gas

Bank Of Montreal

Direxion Daily Semicondct Bull 3X ETF

United States Natural Gas

Guggenheim Solar ETF

VS TR -1x Short VIX Futures ETF

Direxion Daily Financial Bull 3X ETF

Direxion Daily Small Cap Bull 3X ETF

iShares MSCI Japan

Direxion Daily 20+ Yr Trsy Bull 3X ETF

ProShares UltraShort Bloomberg Natrl Gas

VS TR 2x Long VIX Futures ETF

Direxion Daily Semicondct Bear 3X ETF

ProShares Ultra VIX Short-Term Futures

Direxion Financial Bear 3X Shar

Direxion Daily Small Cap Bear 3X ETF

Direxion Daily 20+ Yr Trsy Bear 3X ETF

Direxion Daily S&P Biotech Bear 3X ETF

Direxion Technology Bear 3X Shares

Direxion Daily S&P 500 Bear 3X ETF

Genworth Financial Inc Common Stock

Granite Point Mortgage Trust Inc. Common Stock

JinkoSolar Holding Company Limited American Depositary Shares (each representing 4 Common Shares)

Reddit Inc. Class A Common Stock

RE/MAX Holdings Inc. Class A Common Stock

WESCO International Inc. Common Stock

TKO Group Holdings Inc. Class A Common Stock

ChargePoint Holdings Inc. Common Stock

Bath & Body Works Inc.

Archer Aviation Inc. Class A Common Stock

AgEagle Aerial Systems Inc. Common Stock

Spotify Technology S.A. Ordinary Shares

UBS Group AG Registered Ordinary Shares

Allstate Corporation (The) Common Stock

Telefonica SA Common Stock

Hecla Mining Company Common Stock

ServiceNow Inc. Common Stock

Merck & Company Inc. Common Stock (new)

The AZEK Company Inc. Class A Common Stock

Estee Lauder Companies Inc. (The) Common Stock

Click here to get full coverage on Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha

Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV)  Seeking Alpha

Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha

Click here to get full coverage on VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders - Business Wire

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders  Business Wire

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Click here to get full coverage on Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High?  MSN

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN

Click here to get full coverage on Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus

Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar  GuruFocus

Jefferies Downgrades Verve Therapeutics (VERV), Lowers Price Tar - GuruFocus

Click here to get full coverage on Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk  PR Newswire

Lilly to acquire Verve Therapeutics to advance one-time treatments for people with high cardiovascular risk - PR Newswire

Click here to get full coverage on Stocks making the biggest moves premarket: Sunrun, Verve Therapeutics, T-Mobile and more - CNBC

Stocks making the biggest moves premarket: Sunrun, Verve Therapeutics, T-Mobile and more  CNBC

Stocks making the biggest moves premarket: Sunrun, Verve Therapeutics, T-Mobile and more - CNBC

Click here to get full coverage on Notable Tuesday Option Activity: WLY, VERV, NDSN - Nasdaq

Notable Tuesday Option Activity: WLY, VERV, NDSN  Nasdaq

Notable Tuesday Option Activity: WLY, VERV, NDSN - Nasdaq

Click here to get full coverage on SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates  GlobeNewswire

SHAREHOLDER INVESTIGATION: Halper Sadeh LLC Investigates - GlobeNewswire

Click here to get full coverage on Street View: Lilly locks in heart treatment portfolio with Verve buyout - TradingView

Street View: Lilly locks in heart treatment portfolio with Verve buyout  TradingView

Street View: Lilly locks in heart treatment portfolio with Verve buyout - TradingView

Click here to get full coverage on BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - - Morningstar

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American -  Morningstar

BRODSKY & SMITH SHAREHOLDER UPDATE: Notifying Investors of the Following Investigations: Verve Therapeutics, Inc. (Nasdaq - VERV), Sage Therapeutics, Inc. (Nasdaq - SAGE), Cantaloupe, Inc. (Nasdaq - CTLP), Volato Group, Inc. (NYSE American - - Morningstar

Click here to get full coverage on Stock Movers: Lennar, VERV, T-Mobile - Bloomberg.com

Stock Movers: Lennar, VERV, T-Mobile  Bloomberg.com

Stock Movers: Lennar, VERV, T-Mobile - Bloomberg.com

Click here to get full coverage on What Makes Verve Therapeutics (VERV) a New Buy Stock - Yahoo Finance

What Makes Verve Therapeutics (VERV) a New Buy Stock  Yahoo Finance

What Makes Verve Therapeutics (VERV) a New Buy Stock - Yahoo Finance

Click here to get full coverage on Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus

Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News  GuruFocus

Verve Therapeutics (VERV) Downgraded After Acquisition Agreement | VERV Stock News - GuruFocus

Click here to get full coverage on $VERV stock is up 76% today. Here's what we see in our data. - Nasdaq

$VERV stock is up 76% today. Here's what we see in our data.  Nasdaq

$VERV stock is up 76% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more - CNBC

Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more  CNBC

Stocks making the biggest moves midday: Jabil, JetBlue, Sunrun, Valero, Verve Therapeutics and more - CNBC

Click here to get full coverage on Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus

Verve Therapeutics (VERV) Downgraded Following Acquisition Annou  GuruFocus

Verve Therapeutics (VERV) Downgraded Following Acquisition Annou - GuruFocus

Click here to get full coverage on Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus

Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto  GuruFocus

Verve Therapeutics (VERV) Downgraded by William Blair | VERV Sto - GuruFocus

Click here to get full coverage on Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus

Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News  GuruFocus

Verve Therapeutics (VERV) Downgraded by Canaccord Genuity | VERV Stock News - GuruFocus

Click here to get full coverage on M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - TipRanks

M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly  TipRanks

M&A News: Verve Therapeutics Stock (VERV) Rallies 75% on News of Potential Acquisition by Eli Lilly - TipRanks

Click here to get full coverage on Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus

Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti  GuruFocus

Verve Therapeutics (VERV) Receives Downgrade Following Acquisiti - GuruFocus

Click here to get full coverage on This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga

This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday  Benzinga

This Verve Therapeutics Analyst Is No Longer Bullish; Here Are Top 4 Downgrades For Wednesday - Benzinga

Click here to get full coverage on William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisit - GuruFocus

William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisit  GuruFocus

William Blair Downgrades Verve Therapeutics (VERV) Amid Acquisit - GuruFocus

Click here to get full coverage on Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR - StreetInsider

Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR  StreetInsider

Eli Lilly & Co. (LLY) to acquire Verve Therapeutics (VERV) for $10.50/sh Cash plus CVR - StreetInsider

Click here to get full coverage on Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly  TradingView

Verve Therapeutics Stock Soars 76% on $1.3B Buyout Offer From Lilly - TradingView

Click here to get full coverage on Biotech Stock Surging on Billion-Dollar Buyout - Schaeffer's Investment Research

Biotech Stock Surging on Billion-Dollar Buyout  Schaeffer's Investment Research

Biotech Stock Surging on Billion-Dollar Buyout - Schaeffer's Investment Research

Click here to get full coverage on Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Yahoo Finance

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average  Yahoo Finance

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Yahoo Finance

Click here to get full coverage on Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy?  Yahoo Finance

Is Verve Therapeutics, Inc. (VERV) the Best Gene-Editing Stock to Buy? - Yahoo Finance

Click here to get full coverage on Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - MSN

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates  MSN

Verve Therapeutics (VERV) Reports Q1 Loss, Tops Revenue Estimates - MSN

Click here to get full coverage on Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition - Benzinga

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition  Benzinga

Eli Lilly Expands Into Gene Editing With Verve Therapeutics Acquisition - Benzinga

Click here to get full coverage on Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely  simplywall.st

Verve Therapeutics, Inc. (NASDAQ:VERV) Shares May Have Slumped 26% But Getting In Cheap Is Still Unlikely - simplywall.st

Click here to get full coverage on Verve Therapeutics to Participate in Upcoming Investor Conferences - Stock Titan

Verve Therapeutics to Participate in Upcoming Investor Conferences  Stock Titan

Verve Therapeutics to Participate in Upcoming Investor Conferences - Stock Titan

Click here to get full coverage on Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum - Daily Chhattisgarh News

Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum  Daily Chhattisgarh News

Verve Therapeutics (VERV) Stock Explodes Nearly 80% in a Single Day on Overwhelmingly Positive Momentum - Daily Chhattisgarh News

Click here to get full coverage on Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Nasdaq

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average  Nasdaq

Verve Therapeutics (VERV) Just Reclaimed the 200-Day Moving Average - Nasdaq

Click here to get full coverage on VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - Yahoo Finance

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study  Yahoo Finance

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - Yahoo Finance

Click here to get full coverage on Verve Therapeutics Expands Team: 7 New Hires Receive Major Equity Package Worth $1.1M - Stock Titan

Verve Therapeutics Expands Team: 7 New Hires Receive Major Equity Package Worth $1.1M  Stock Titan

Verve Therapeutics Expands Team: 7 New Hires Receive Major Equity Package Worth $1.1M - Stock Titan

Click here to get full coverage on Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards - Stock Titan

Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards  Stock Titan

Latest Employee Stock Grants: Verve Therapeutics Issues 87,000 Shares Worth of Equity Awards - Stock Titan

Click here to get full coverage on Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher  Yahoo Finance

Analyst Forecasts For Verve Therapeutics, Inc. (NASDAQ:VERV) Are Surging Higher - Yahoo Finance

Click here to get full coverage on Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - Nasdaq

Cantor Fitzgerald Upgrades Verve Therapeutics (VERV)  Nasdaq

Cantor Fitzgerald Upgrades Verve Therapeutics (VERV) - Nasdaq

Click here to get full coverage on $VERV stock is up 11% today. Here's what we see in our data. - Nasdaq

$VERV stock is up 11% today. Here's what we see in our data.  Nasdaq

$VERV stock is up 11% today. Here's what we see in our data. - Nasdaq

Click here to get full coverage on VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - Zacks Investment Research

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study  Zacks Investment Research

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - Zacks Investment Research

Click here to get full coverage on Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - TradingView

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News  TradingView

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - TradingView

Click here to get full coverage on Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In?  Yahoo Finance

Why Is Verve Therapeutics, Inc. (VERV) Among the Top CRISPR Stocks to Invest In? - Yahoo Finance

Click here to get full coverage on Jefferies maintains $28 target on VERV stock, cites upside potential - Investing.com

Jefferies maintains $28 target on VERV stock, cites upside potential  Investing.com

Jefferies maintains $28 target on VERV stock, cites upside potential - Investing.com

Click here to get full coverage on Long Term Trading Analysis for (VERV) - news.stocktradersdaily.com

Long Term Trading Analysis for (VERV)  news.stocktradersdaily.com

Long Term Trading Analysis for (VERV) - news.stocktradersdaily.com

Click here to get full coverage on Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan

Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol  Stock Titan

Game-Changing FDA Green Light: Verve's One-Time Gene Therapy Takes On High Cholesterol - Stock Titan

Click here to get full coverage on News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts  simplywall.st

News Flash: Analysts Just Made An Incredible Upgrade To Their Verve Therapeutics, Inc. (NASDAQ:VERV) Forecasts - simplywall.st

Click here to get full coverage on Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status - Stock Titan

Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status  Stock Titan

Revolutionary Gene Editing Drug for Heart Disease Earns FDA Fast Track Status - Stock Titan

Click here to get full coverage on Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now?  Yahoo Finance

Verve Therapeutics, Inc. (VERV): Is This Gene Therapy Stock a Good Buy Right Now? - Yahoo Finance

Click here to get full coverage on VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - TradingView

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study  TradingView

VERV Stock Soars on Superior Efficacy in Phase I Cholesterol Study - TradingView

Click here to get full coverage on Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News  Yahoo Finance

Biotech Stock Roundup: BMY Down on Study Failure, VERV Up on Study Data & More News - Yahoo Finance

Click here to get full coverage on (VERV) Investment Analysis - news.stocktradersdaily.com

(VERV) Investment Analysis  news.stocktradersdaily.com

(VERV) Investment Analysis - news.stocktradersdaily.com

Click here to get full coverage on SA analyst upgrades: AMD, PLTR, VKTX, HUBS, MO, USB, SFIX, VERV - Seeking Alpha

SA analyst upgrades: AMD, PLTR, VKTX, HUBS, MO, USB, SFIX, VERV  Seeking Alpha

SA analyst upgrades: AMD, PLTR, VKTX, HUBS, MO, USB, SFIX, VERV - Seeking Alpha

Click here to get full coverage on Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha

Verve stock jumps on early-stage trial data (VERV:NASDAQ)  Seeking Alpha

Verve stock jumps on early-stage trial data (VERV:NASDAQ) - Seeking Alpha

Click here to get full coverage on (VERV) Trading Advice - news.stocktradersdaily.com

(VERV) Trading Advice  news.stocktradersdaily.com

Verve Therapeutics Inc (VERV)

Price Chart

Key Statistics

Technicals

About VERV

Latest News

Lock In The 81.5% Run: Initiating Verve With A Sell (NASDAQ:VERV) - Seeking Alpha

VERV Stock Alert: Halper Sadeh LLC Is Investigating Whether the Sale of Verve Therapeutics, Inc. Is Fair to Shareholders - Business Wire

Wall Street Analysts See a 367.86% Upside in Verve Therapeutics (VERV): Can the Stock Really Move This High? - MSN

Advanced Charts

Top Gainers

Top Losers